Ardance-L 25 mg+5 mg (Tablet)

Unit Price: ৳ 40.00 (3 x 10: ৳ 1,200.00)
Strip Price: ৳ 400.00

Medicine Details

Category Details
Generic Empagliflozin linagliptin
Company Pharmacil limited
Also available as
Ardance l 10 mg tablet

Indications

  • Adjunct to diet and exercise
  • Improves glycemic control
  • Type 2 diabetes mellitus

Pharmacology

  • Inhibits DPP-4 enzyme
  • Increases active incretin hormones
  • Stimulates insulin release
  • Decreases glucagon levels
  • Reduces renal reabsorption of glucose

Dosage & Administration

  • 10 mg Empagliflozin and 5 mg Linagliptin once daily
  • Increased dose to 25 mg Empagliflozin and 5 mg Linagliptin once daily
  • Assess renal function before initiating
  • Discontinue if eGFR falls below 45 ml/min/1.73 m²

Interaction

  • Diuretics - increases urine volume and frequency of voids
  • Insulin or Insulin Secretagogues - increases risk for hypoglycemia
  • Inducers of P-glycoprotein or CYP3A4 Enzymes - may reduce efficacy
  • Positive Urine Glucose Test - leads to positive urine glucose tests
  • Interference with 1,5-anhydroglucitol (1,5-AG) Assay - unreliable measurements

Contraindications

  • Severe renal impairment
  • End-stage renal disease or dialysis
  • Hypersensitivity reaction to Linagliptin or Empagliflozin

Side Effects

  • Pancreatitis
  • Ketoacidosis
  • Volume Depletion
  • Urosepsis and Pyelonephritis
  • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
  • Necrotizing Fasciitis of the Perineum
  • Genital Mycotic Infections
  • Hypersensitivity Reactions
  • Severe and Disabling Arthralgia
  • Bullous Pemphigoid
  • Heart Failure

Pregnancy & Lactation

  • Not recommended during second and third trimesters
  • Limited available data in pregnant women

Precautions & Warnings

  • Precaution in conditions like Pancreatitis, Hypotension, Ketoacidosis, Acute kidney injury, Urosepsis, Hypoglycemia, Genital Mycotic Infections, Hypersensitivity
  • Acute pancreatitis, including fatal pancreatitis, reported
  • Reports of ketoacidosis
  • Empagliflozin can cause intravascular volume depletion
  • Increases risk for urinary tract infections
  • Known to cause hypoglycemia
  • Reports of necrotizing infections
  • Increases risk for genital mycotic infections
  • Association between DPP-4 inhibitor treatment and heart failure observed

Overdose Effects

  • Contact Poison Control Center
  • Use usual supportive measures
  • Removal of Empagliflozin by hemodialysis not studied
  • Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely

Therapeutic Class

  • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

  • Store below 30°C
  • Keep away from light and wet place
  • Keep out of reach of children

Related Brands